Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Few Questions From FDA, Cinryze Seems Set For Smooth Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will review Cinryze only for prophylaxis of hereditary angioedema at Blood Products advisory panel meeting May 2, leaving open the possibility of a split indication.

You may also be interested in...



ViroPharma Looks To Enter HAE Market With Lev Acquisition

Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.

ViroPharma Looks To Enter HAE Market With Lev Acquisition

Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.

Lev’s Cinryze Wins Unanimous Advisory Committee Support

Postmarketing studies likely will be required for what could be the first U.S. treatment for hereditary angioedema.

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel